Evidence map›Paper›PMID 36683682›Full record

ArticleFrontiers in cellular and infection microbiology2022

Vancomycin-nanofunctionalized peptide-enriched silk fibroin to prevent methicillin-resistant

Marta Bottagisio, Silvia Palombella, Silvia Lopa, Fabio Sangalli, Paolo Savadori, Marco Biagiotti, Zili Sideratou, Dimitris Tsiourvas, Arianna B Lovati

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Draft genome ofMicrobiology resource announcements · 2025
    Article
  3. Article
  4. Review
  5. Review
  6. SMR peptide antagonizesMicrobiology spectrum · 2024
    Article
  7. Review
  8. Silk Fibroin/ZnO Coated TiOMaterials (Basel, Switzerland) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Marta BottagisioIRCCS Istituto Ortopedico Galeazzi, Laboratory of Clinical Chemistry and Microbiology, Milan, Italy.
Silvia PalombellaIRCCS Istituto Ortopedico Galeazzi, Cell and Tissue Engineering Laboratory, Milan, Italy.
Silvia LopaIRCCS Istituto Ortopedico Galeazzi, Cell and Tissue Engineering Laboratory, Milan, Italy.
Fabio SangalliIRCCS Istituto di Ricerche Farmacologiche Mario Negri, Laboratory of Renal Biophysics, Department of Biomedical Engineering, Bergamo, Italy.
Paolo SavadoriIRCCS Istituto Ortopedico Galeazzi, Department of Endodontics, Milan, Italy.
Marco BiagiottiSilk Biomaterials srl, Lomazzo, Italy.
Zili SideratouNational Centre for Scientific Research "Demokritos", Institute of Nanoscience and Nanotechnology, Aghia Paraskevi, Greece.
Dimitris TsiourvasNational Centre for Scientific Research "Demokritos", Institute of Nanoscience and Nanotechnology, Aghia Paraskevi, Greece.
Arianna B LovatiIRCCS Istituto Ortopedico Galeazzi, Cell and Tissue Engineering Laboratory, Milan, Italy.
Istituto Ortopedico Galeazzi · ITNational Centre of Scientific Research "Demokritos" · GRInstitute of Polymers, Composites and Biomaterials · ITMario Negri Institute for Pharmacological Research · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Implant-related infections and infected fractures are significant burdens in orthopedics. Methods: To this end, a recently developed in our laboratories bioactive material consisting of antibiotic-loaded nanoparticles based on carboxylic acid functionalized hyperbranched aliphatic polyester (CHAP) that are integrated into peptide-enriched silk fibroin sponges with osteoconductive properties (AFN-PSF) was employed, whose biocompatibility and microbiological tests provided proof of its potential for the treatment of both orthopedic and dental infections. In particular, non-critical femoral fractures fixed with plates and screws were performed in Wistar rats, which were then randomly divided into three groups: 1) the sham control (no infection, no treatment); 2) the control group, infected with MRSE and treated with peptide-enriched silk fibroin sponges incorporating non-drug-loaded functionalized nanoparticles (PSF); 3) the treated group, infected with MRSE and treated with peptide-enriched silk fibroin sponges incorporating vancomycin-loaded functionalized nanoparticles (AFN-PSF). After 8 weeks, bone healing and osteomyelitis were clinically assessed and evaluated by micro-CT, microbiological and histological analyses. Results: The sham group showed no signs of infection and complete bone healing. The PSF group failed to repair the infected fracture, displaying 75% of altered bone healing and severe signs of osteomyelitis. The AFN-PSF treated group reached 70% of fracture healing in the absence of signs of osteomyelitis, such as abscesses in the cortical and intraosseous compartments and bone necrosis with sequestra. Discussion: AFN-PSF sponges have proven effective in preventing the development of infected nonunion

Indexed as

FibroinsMethicillin-Resistant Staphylococcus aureusOsteomyelitisStaphylococcal InfectionsAnimalsAnti-Bacterial AgentsMethicillin ResistanceRatsRats, WistarStaphylococcus epidermidisVancomycinAnti-Bacterial AgentsFibroinsVancomycinbiofilmimplant-related bone infectionslocal antibiotic deliverynanoparticlesosteoconductive peptidespreventionsilk fibroinStaphylococcus epidermidis

Identifiers

PMID36683682
PMCPMC9851397
OpenAlexW4313569758

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.